Beijing Biostar Pharmaceuticals Co., Ltd.

Beijing Biostar Pharmaceuticals Co Ltd is a China-based company principally engaged in the research, development, production and sales of innovative drugs. A synthetic biology-driven biopharmaceutical company, engages in the research and development, production, and commercialization of oncology products. The Company's products and pipeline mainly include Utidelone Injection, Utidelone Capsule, Utidelone Nanoformulation, Utidelone Antibody Drug Conjugate (ADC), BG22, BG18 and BG44. The Company's products are principally used for the treatment of relapsed or metastatic breast cancer, neoadjuvant treatment of human epidermal growth factor receptor 2 (HER2)-breast cancer neoadjuvant, advanced non-small cell lung cancer (NSCLC), solid tumors, breast cancer brain metastasis, lung cancer brain metastasis and other brain tumor indications. The Company mainly conducts its businesses in the domestic market. Integrated capabilities encompassing R&D, manufacturing and commercialization. Advanced and sustainable synthetic biology platforms. Building first- and best-in-class portfolios to address major unmet medical needs. As an innovative cancer drug company driven by synthetic biology technology, Beijing Biostar successfully listed in Hong Kong.